Scientific literature

The table below lists 26 publications that have reported genetic associations for Levodopa-induced dyskinesia in Parkinson's disease. You can sort the table according to a certain column by clicking on the column name. You can also download the data. If you think that we missed a publication, please help us to further improve this resource by contacting us.

ReferenceTitlePubmed IDNote
Bialecka et al. 2004Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease.15355491Gene/variant curated
Cheshire al. 2014Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease.24008922Gene/variant curated
Contin et al. 2005Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.15747357No gene/variant curated
de Lau et al. 2011Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease.22083803Gene/variant curated
Foltynie et al. 2009BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease.18977816Gene/variant curated
Greenbaum et al. 2013Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.23666822No gene/variant curated
Hao et al. 2014Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson's disease in a Chinese population.25034874Gene/variant curated
Healy et al. 2008Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.18539534Gene/variant curated
Ivanova et al. 2012NMDA receptor genotypes associated with the vulnerability to develop dyskinesia.22832729No gene/variant curated
Kaiser et al. 2003L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.12796525Gene/variant curated
Kaplan et al. 2014Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.24633632Gene/variant curated
Lee et al. 2011Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease.20945430Gene/variant curated
Lesage et al. 2008Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease?18981379Gene/variant curated
Lin et al. 2007Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.17196621No gene/variant curated
Molchadski et al. 2011The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia.21108621No gene/variant curated
Oliveri et al. 1999Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD.10534246Gene/variant curated
Paus et al. 2009Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism.19353703No gene/variant curated
Rieck et al. 2012DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients.23171335Gene/variant curated
Rieck et al. 2015Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients?25872644Gene/variant curated
Rivera-Calimlim et al. 1984Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance.6734032No gene/variant curated
Schumacher-Schuh et al. 2014Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients.24126708Gene/variant curated
Strong et al. 2006Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.16435402Gene/variant curated
Torkaman-Boutorabi et al. 2012The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease.23093014No gene/variant curated
Watanabe et al. 2003Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease.14673217No gene/variant curated
Yahalom et al. 2012Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.22703868No gene/variant curated
Zappia et al. 2005Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.15824260Gene/variant curated